샘플 요청 목록

 카트 문의
시장보고서
상품코드
1796066

세계의 급성 편두통 치료 시장

Acute Migraine Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 374 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

급성 편두통 치료 세계 시장은 2030년까지 94억 달러에 달할 전망

2024년에 40억 달러로 추정되는 급성 편두통 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 15.3%로 성장하여 2030년에는 94억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 트립탄 제제는 CAGR 17.2%를 기록하며 분석 기간 종료시에는 30억 달러에 달할 것으로 예측됩니다. CAGR 길항제 부문은 분석 기간 동안 CAGR 성장률이 13.0%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 20.5%로 성장 예측

미국의 급성 편두통 치료 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 21억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 20.5%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 11.1%와 13.8%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.2%로 성장할 것으로 예측됩니다.

세계의 급성 편두통 치료 시장 - 주요 동향과 촉진요인 정리

급성 편두통 치료는 증가하는 환자 집단의 요구를 충족시키기 위해 어떻게 진화하고 있는가?

임상의, 연구자, 제약회사들이 이 쇠약성 신경질환으로 고통받는 환자들의 증가하는 요구에 부응하기 위해 노력하면서 급성 편두통의 치료 환경은 크게 변화하고 있습니다. 욱신거리는 통증, 메스꺼움, 광맹, 환청을 특징으로 하는 급성 편두통 발작은 일상 생활 기능과 삶의 질을 심각하게 손상시킵니다. 기존 치료는 비스테로이드성 항염증제(NSAIDs)와 같은 비특이적 진통제나 1990년대에 표준이 된 세로토닌 수용체 작용제의 일종인 트립탄계 항염증제에 의존하는 경우가 많았습니다. 이러한 약물은 많은 환자들에게 완화를 가져다 주었지만, 모든 환자, 특히 혈관수축제를 안전하게 사용할 수 없는 심혈관계 합병증을 가진 환자들에게 효과적이거나 잘 견딜 수 있는 것은 아닙니다. 게판츠(CGRP 수용체 길항제)나 다이탄(세로토닌 5-HT1F 수용체 작용제)과 같은 새로운 계열의 약물의 출현은 편두통의 근본적인 병태생리를 표적으로 삼는 데 있어 중요한 도약을 의미합니다. 이 약제들은 기존 치료에 수반되는 심혈관계 위험 없이 효능을 나타내며, 보다 광범위한 환자에게 사용할 수 있습니다. 경구용 약품 외에도 비강용액, 주사제, 빠르게 녹는 정제가 도입되어 보다 빠른 완화와 간편한 투여가 가능해졌습니다. 이러한 치료법의 진화는 빠른 발병, 부작용 감소, 내약성 향상에 중점을 둔 환자 중심 치료로의 전환을 반영하고 있습니다. 편두통이 공중보건에 미치는 영향에 대한 인식이 높아짐에 따라 의료진과 환자 모두 조기에 효과적인 개입을 옹호하고 있으며, 급성기 치료 분야의 연구와 혁신이 촉진되고 있습니다.

급성 편두통 치료제 시장에서 신약이 급격한 성장세를 보이는 이유는 무엇일까?

급성 편두통 치료제 시장에서 약효를 발휘하는 약물 계열별 신약은 편두통 발작에 관여하는 생화학적 과정을 표적으로 삼는 작용 기전을 제공하기 때문에 급성 편두통 치료 시장에서 성장세를 보이고 있습니다. 최근 가장 중요한 동향 중 하나는 게판토로 알려진 CGRP(칼시토닌 유전자 관련 펩타이드) 수용체 길항제 개발입니다. CGRP는 뇌혈관의 염증과 혈관 확장을 촉진하여 편두통 발병에 매우 중요한 역할을 하는 것으로 알려진 신경 펩타이드입니다. 우브로게판트, 리메게판트 등 여러 국가에서 승인된 게판트는 심혈관계 위험인자를 가진 환자들에게 안전한 비혈관수축성 치료제를 제공하고 있습니다. 마찬가지로, 라스미디탄과 같은 디탄은 세로토닌 5-HT1F 수용체에 작용하여 혈관 수축을 일으키지 않고 편두통과 관련된 통증 신호 전달을 억제합니다. 이러한 새로운 치료법은 임상의에게 매력적인 치료법입니다. 이는 약효 발현 지연, 약물 과용에 따른 두통, 취약 계층의 금기 사항 등 기존 치료의 한계를 피하면서 급성 완화를 가져다주기 때문입니다. 또한, 약물전달 시스템의 발전으로 인해 생체 이용률과 환자 순응도가 향상되고 있습니다. 비강 분무제나 구강 용해 정제와 같은 제제는 정제를 삼키기 어려운 편두통 활동 중에 더 빨리 흡수되고 복용이 용이합니다. 임상시험에서 이 새로운 치료법은 내약성이 좋고, 소화기 부작용이 적으며, 약물 과다 복용의 위험이 낮은 것으로 나타났습니다. 규제 당국의 승인 확대와 안전성 및 유효성을 뒷받침하는 실제 임상 데이터로 인해 이러한 새로운 치료제는 급성 편두통 관리 방식을 바꾸고 있으며, 전 세계적으로 치료 가이드라인을 재평가하도록 유도하고 있습니다.

환자 개개인에 맞는 급성 편두통 치료를 위해 임상의가 고려해야 할 중요한 사항은 무엇인가?

급성 편두통 치료를 관리하는 임상의는 치료법을 조정할 때 효과, 내약성, 동반 질환, 환자의 선호도 사이에서 균형을 맞춰야 하며, 이 영역에서 맞춤형 치료가 점점 더 중요해지고 있습니다. 기존의 트립탄계 약물은 혈관수축 작용이 있기 때문에 뇌졸중, 심장병, 조절되지 않는 고혈압 병력이 있는 환자에게는 금기입니다. 이런 환자에게는 게팬츠나 다이탄과 같은 새로운 대안이 더 안전한 선택이 될 수 있습니다. 또 다른 요인은 편두통 발작의 빈도와 강도입니다. 편두통 발작 빈도가 낮은 환자에게는 NSAIDs나 트립탄계 약물이 잘 듣지만, 발작 빈도가 높거나 치료 저항성이 있는 편두통 환자에게는 차세대 약물이나 병용요법이 필요합니다. 임상의는 치료 시작 시기도 고려해야 합니다. 편두통이 경미한 단계에서 조기에 개입하는 것이 통증이 심해진 후에 치료하는 것보다 더 효과적이기 때문입니다. 약물의 투여 방법도 중요한 고려 사항입니다. 편의성 때문에 경구용 정제를 선호하는 환자도 있지만, 발작 시 메스꺼움이나 구토가 동반되는 경우 비강정이나 주사제 등 경구용 이외의 선택이 필요한 환자도 있습니다. 부작용 프로파일, 약물 간 상호작용 가능성, 사용 편의성 등이 모두 순응도와 환자 만족도에 영향을 미칩니다. 또한, 환자의 치료 이력이나 약물 과다 사용으로 인한 두통의 병력을 파악하는 것은 증상을 악화시키지 않기 위해 필수적입니다. 다양한 치료 옵션을 이용할 수 있게 됨에 따라 임상의는 결과를 최적화하고 환자 경험을 향상시킬 수 있는 개별화 전략을 수립할 수 있게 되었습니다. 공동 의사결정이 표준 치료가 되면서 환자가 치료법 선택에 참여하는 것은 편두통 발작의 급성기 치료의 장기적인 성공을 위해 필수적입니다.

세계 급성 편두통 치료 시장의 성장을 촉진하는 요인은 무엇인가?

급성 편두통 치료 시장의 세계 성장은 편두통 치료에 대한 접근 방식을 재구성하고 있는 역학, 기술, 규제, 소비자 중심적 요인의 조합에 의해 주도되고 있습니다. 우선, 전 세계적으로 편두통의 높은 유병률과 10억 명으로 추산되는 편두통 환자 수는 더 나은, 더 빠른 증상 완화를 원하는 방대한 미치료 환자층을 형성하고 있습니다. 편두통이 심각하고 장애를 동반하는 신경질환이라는 인식이 높아짐에 따라 의료시스템은 진단과 치료에 많은 자원을 투입하고 있습니다. 많은 국가에서 편두통 치료제가 국가 처방전에 포함되면서 기존 치료제와 혁신적 치료제에 대한 환자들의 접근성이 향상되고 있습니다. 기술적 측면에서 제약회사는 분자생물학 및 신경과학의 발전을 활용하여 CGRP 및 세로토닌 아형과 같은 편두통 발작에 관여하는 특정 경로를 표적으로 삼는 보다 정밀한 약물을 개발하고 있습니다. FDA 및 EMA와 같은 규제 기관은 패스트트랙 및 혁신적 치료법 지정과 같은 메커니즘을 통해 승인을 신속히 처리함으로써 편두통 환자의 미충족 수요를 충족시키고 있습니다. 이를 통해 개발 기간을 단축하고 새로운 치료제를 보다 빠르게 시장에 출시할 수 있게 되었습니다. 부작용이 적고 효과가 빠르며 안전성 프로파일이 넓은 치료에 대한 환자들의 요구는 의약품 연구 개발의 우선순위에 영향을 미치고 제품 차별화를 촉진하고 있습니다. 또한, 디지털 건강 플랫폼과 편두통 추적 앱의 성장으로 더 나은 데이터 수집과 질병 관리가 가능해져 보다 개인화되고 신속한 치료 접근이 가능해졌습니다. 환자 옹호 단체와 전문가 협회의 교육 활동도 전 세계 치료 수준을 높이고 있습니다. 이러한 힘을 종합하면 급성 편두통 치료 시장의 확대에 박차를 가할 뿐만 아니라, 편두통 치료가 보다 접근하기 쉽고 효과적이며 환자 개개인의 요구에 부합하는 미래로 나아갈 수 있는 길이 열리고 있습니다.

부문

약물 유형(트립탄계 약제, CGRP 길항제, 비스테로이드성 항염증제, β-아드레날린 차단제, 에르고트 알칼로이드 약제, 기타 약물 유형), 투여 경로(경구 투여, 주사 투여, 기타 투여 경로), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업 사례

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biohaven Ltd.
  • CoLucid Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc(GSK)
  • H. Lundbeck A/S
  • Impel Pharmaceuticals Inc.
  • Johnson & Johnson(Janssen)
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries
  • Tonix Pharmaceuticals
  • Zosano Pharma Corporation

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.02

Global Acute Migraine Treatment Market to Reach US$9.4 Billion by 2030

The global market for Acute Migraine Treatment estimated at US$4.0 Billion in the year 2024, is expected to reach US$9.4 Billion by 2030, growing at a CAGR of 15.3% over the analysis period 2024-2030. Triptans Drug, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the CGRP Antagonist Drug segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 20.5% CAGR

The Acute Migraine Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Acute Migraine Treatment Market - Key Trends & Drivers Summarized

How Is Acute Migraine Treatment Evolving to Address the Needs of a Growing Patient Population?

The treatment landscape for acute migraine is undergoing significant transformation as clinicians, researchers, and pharmaceutical companies strive to address the growing needs of patients who suffer from this debilitating neurological disorder. Acute migraine attacks, characterized by throbbing pain, nausea, photophobia, and phonophobia, can severely impair daily functioning and quality of life. Traditionally, treatments have relied heavily on non-specific pain relievers such as NSAIDs, and triptans, a class of serotonin receptor agonists that became the gold standard in the 1990s. While these drugs have provided relief for many, they are not effective or tolerable for all patients, especially those with cardiovascular comorbidities who cannot safely use vasoconstrictive medications. The emergence of newer classes of medications such as gepants (CGRP receptor antagonists) and ditans (serotonin 5-HT1F receptor agonists) represents a critical leap forward in targeting the underlying pathophysiology of migraines. These drugs offer efficacy without the cardiovascular risks associated with older treatments and can be used in a broader range of patients. In addition to oral medications, nasal sprays, injectables, and rapidly dissolving tablets are being introduced to offer faster relief and more convenient administration. This evolution in treatment modalities reflects a shift toward patient-centric care, emphasizing rapid onset, reduced side effects, and improved tolerability. As awareness of migraine’s impact on public health increases, both healthcare providers and patients are advocating for early and effective intervention, which is propelling research and innovation in the acute treatment space.

Why Are New Drug Classes Gaining Momentum in the Acute Migraine Treatment Market?

New drug classes are gaining momentum in the acute migraine treatment market because they offer mechanisms of action specifically designed to target the biochemical processes involved in migraine attacks. One of the most important breakthroughs in recent years has been the development of CGRP (calcitonin gene-related peptide) receptor antagonists, known as gepants. CGRP is a neuropeptide believed to play a pivotal role in migraine pathogenesis by promoting inflammation and vasodilation in cerebral blood vessels. Gepants such as ubrogepant and rimegepant have been approved in several countries and offer a non-vasoconstrictive option that is safe for individuals with cardiovascular risk factors. Similarly, ditans like lasmiditan work on serotonin 5-HT1F receptors to inhibit migraine-related pain signaling without causing blood vessel constriction, addressing an important gap left by triptans. These novel therapies are appealing to clinicians because they provide acute relief while avoiding the limitations associated with older treatments, including delayed onset of action, drug overuse headaches, and contraindications in vulnerable populations. Furthermore, advancements in drug delivery systems are improving bioavailability and patient adherence. Formulations such as intranasal sprays and oral dissolvable tablets allow for faster absorption and easier administration during an active migraine, when swallowing pills may be difficult. Clinical trials have also shown these newer treatments to be well tolerated, with fewer gastrointestinal side effects and lower risks of medication overuse. With regulatory approvals expanding and real-world data supporting their safety and efficacy, these new classes are reshaping how acute migraines are managed and prompting a reevaluation of treatment guidelines across the globe.

What Are the Key Considerations for Clinicians in Tailoring Acute Migraine Therapy to Individual Patients?

Clinicians managing acute migraine treatment must balance efficacy, tolerability, comorbidities, and patient preferences when tailoring therapy, making personalized care increasingly important in this space. One of the most critical considerations is the patient’s cardiovascular health, as traditional triptans are contraindicated in individuals with a history of stroke, heart disease, or uncontrolled hypertension due to their vasoconstrictive effects. For these patients, newer options like gepants and ditans offer safer alternatives. Another factor is the frequency and intensity of migraine attacks. Patients with infrequent attacks may respond well to NSAIDs or triptans, while those with more frequent or treatment-resistant migraines may require access to next-generation medications or combination therapies. Clinicians must also consider the timing of treatment initiation, as early intervention during the mild phase of a migraine is typically more effective than delayed treatment after pain has escalated. The mode of drug administration is another vital consideration. Some patients prefer oral tablets for convenience, while others may require non-oral options such as nasal sprays or injectables if nausea or vomiting accompanies their attacks. Side effect profiles, potential drug-drug interactions, and ease of use all factor into adherence and overall patient satisfaction. Additionally, understanding a patient's prior treatment history and any history of medication overuse headaches is essential to avoid compounding the condition. With the increasing availability of diverse treatment options, clinicians are now better equipped to design individualized strategies that optimize outcomes and enhance the patient experience. As shared decision-making becomes a standard of care, involving patients in choosing their treatment options is critical for long-term success in managing acute migraine attacks.

What Forces Are Driving Growth in the Global Acute Migraine Treatment Market?

The global growth of the acute migraine treatment market is being driven by a combination of epidemiological, technological, regulatory, and consumer-focused factors that are reshaping the approach to migraine care. First and foremost, the high prevalence of migraines worldwide, affecting an estimated one billion people, has established a vast and underserved patient base that continues to seek better and faster relief from symptoms. As awareness of migraine as a serious and disabling neurological condition grows, healthcare systems are investing more resources into diagnosis and treatment. The expansion of health insurance coverage in many countries and the increasing inclusion of migraine therapies in national formularies are also improving patient access to both traditional and innovative medications. On the technology front, pharmaceutical companies are leveraging advances in molecular biology and neuroscience to develop more precise drugs that target the specific pathways involved in migraine attacks, such as CGRP and serotonin subtypes. Regulatory agencies like the FDA and EMA are responding to the unmet needs of migraine patients by expediting approvals through mechanisms like fast-track and breakthrough designations. This has shortened development timelines and brought new therapies to market more quickly. Patient demand for treatments with fewer side effects, rapid onset of action, and broader safety profiles is influencing pharmaceutical R&D priorities and driving product differentiation. Moreover, the growth of digital health platforms and migraine tracking apps is enabling better data collection and disease management, fostering more personalized and responsive treatment approaches. Education efforts by patient advocacy groups and professional societies are also raising standards of care globally. Collectively, these forces are not only fueling the expansion of the acute migraine treatment market but also paving the way for a future where migraine care is more accessible, effective, and aligned with individual patient needs.

SCOPE OF STUDY:

The report analyzes the Acute Migraine Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug, Other Drug Types); Administration Route (Oral Administration, Injection Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biohaven Ltd.
  • CoLucid Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc (GSK)
  • H. Lundbeck A/S
  • Impel Pharmaceuticals Inc.
  • Johnson & Johnson (Janssen)
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries
  • Tonix Pharmaceuticals
  • Zosano Pharma Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Acute Migraine Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Migraine Throws the Spotlight on the Expanding Acute Migraine Treatment Market
    • Increased Awareness and Diagnosis Rates Propel Growth in Demand for Fast-Acting Therapeutic Options
    • Advancements in CGRP Receptor Antagonists and Ditans Drive Adoption of Targeted Non-Triptan Therapies
    • Shift Away from Opioid-Based Pain Management Strengthens Business Case for Safer, Migraine-Specific Medications
    • Here's the Story: Neurologists and Primary Care Providers Turning to New Drug Classes for Refractory Migraine Cases
    • Rise of Digital Health Tools and Telemedicine Accelerates Access to Acute Migraine Medications and Management Plans
    • Growing Use of Self-Injectable Devices and Orally Disintegrating Tablets Enhances Patient Compliance and Convenience
    • Expansion of Over-the-Counter (OTC) Options and Combination Formulations Spurs Consumer-Driven Market Growth
    • Pharmaceutical Innovation in Nasal Sprays and Inhalable Delivery Systems Sustains Focus on Rapid-Onset Relief
    • Chronic Migraine Sufferers Driving Dual Use of Preventive and Acute Therapies Boost Market Potential
    • Rising Demand for Non-Invasive Neuromodulation Devices Opens New Avenues for Acute Migraine Relief
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Migraine Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Triptans Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for CGRP Antagonist Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for NSAID Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ergot Alkaloids Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Injection Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • JAPAN
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CHINA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • EUROPE
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • FRANCE
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • GERMANY
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • INDIA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AFRICA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제